1. Home
  2. LCFY vs ENSC Comparison

LCFY vs ENSC Comparison

Compare LCFY & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LCFY
  • ENSC
  • Stock Information
  • Founded
  • LCFY 2009
  • ENSC 2003
  • Country
  • LCFY Australia
  • ENSC United States
  • Employees
  • LCFY N/A
  • ENSC N/A
  • Industry
  • LCFY
  • ENSC Biotechnology: Pharmaceutical Preparations
  • Sector
  • LCFY
  • ENSC Health Care
  • Exchange
  • LCFY Nasdaq
  • ENSC Nasdaq
  • Market Cap
  • LCFY 5.9M
  • ENSC 5.5M
  • IPO Year
  • LCFY 2022
  • ENSC N/A
  • Fundamental
  • Price
  • LCFY $4.39
  • ENSC $2.11
  • Analyst Decision
  • LCFY
  • ENSC
  • Analyst Count
  • LCFY 0
  • ENSC 0
  • Target Price
  • LCFY N/A
  • ENSC N/A
  • AVG Volume (30 Days)
  • LCFY 5.0M
  • ENSC 67.4K
  • Earning Date
  • LCFY 07-22-2025
  • ENSC 08-13-2025
  • Dividend Yield
  • LCFY N/A
  • ENSC N/A
  • EPS Growth
  • LCFY N/A
  • ENSC N/A
  • EPS
  • LCFY N/A
  • ENSC N/A
  • Revenue
  • LCFY $2,668,385.00
  • ENSC $6,224,081.00
  • Revenue This Year
  • LCFY N/A
  • ENSC N/A
  • Revenue Next Year
  • LCFY N/A
  • ENSC $1,381.48
  • P/E Ratio
  • LCFY N/A
  • ENSC N/A
  • Revenue Growth
  • LCFY N/A
  • ENSC 256.35
  • 52 Week Low
  • LCFY $2.51
  • ENSC $1.62
  • 52 Week High
  • LCFY $13.98
  • ENSC $14.67
  • Technical
  • Relative Strength Index (RSI)
  • LCFY 49.68
  • ENSC 44.44
  • Support Level
  • LCFY $4.12
  • ENSC $1.97
  • Resistance Level
  • LCFY $5.40
  • ENSC $2.40
  • Average True Range (ATR)
  • LCFY 1.22
  • ENSC 0.17
  • MACD
  • LCFY -0.05
  • ENSC -0.00
  • Stochastic Oscillator
  • LCFY 16.39
  • ENSC 32.56

About LCFY Locafy Limited

Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: